R&D investment into novel antimicrobials crucial, analyst says

27 November 2023

An expert has called for governments and industry to make investing in novel antimicrobials a priority.

Fiona Chisholm, associate director of infectious diseases at analytics and data company GlobalData, spoke about the urgency of the issue during World Antimicrobial Resistance (AMR) Awareness Week (WAAW).

"Alleviating the impacts of AMR represents one of the greatest challenges facing humanity"While AMR is not a new problem, it has reached critical levels in recent years due to the overuse and misuse of antimicrobials in humans and animals, as well as inadequate infection prevention and control

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK